954124-35-7Relevant academic research and scientific papers
NAMPT MODULATORS
-
, (2021/08/13)
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
-
Page/Page column 165, (2010/08/04)
The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.
Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
Wilson, Kenneth J.,Illig, Carl R.,Chen, Jinsheng,Wall, Mark J.,Ballentine, Shelley K.,Desjarlais, Renee L.,Chen, Yanmin,Schubert, Carsten,Donatelli, Robert,Petrounia, Ioanna,Crysler, Carl S.,Molloy, Christopher J.,Chaikin, Margery A.,Manthey, Carl L.,Player, Mark R.,Tomczuk, Bruce E.,Meegalla, Sanath K.
scheme or table, p. 3925 - 3929 (2010/09/03)
During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead ary
INHIBITORS OF C-FMS KINASE
-
Page/Page column 28, (2008/06/13)
The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, es
